Pfizer Planning To Start Phase III DMD Gene Therapy Trial, With Safety Monitoring Protocols

Updated Phase Ib data showed safety issues due to complement activation, but Pfizer is confident the benefits outweigh the risks and monitoring systems will help as it moves into Phase III.

Caution sign
Positive efficacy signals but safety risks too with Pfizer's DMD gene therapy • Source: Shutterstock

Pfizer Inc. will begin enrolling boys with Duchenne muscular dystrophy in a Phase III clinical trial in the second half of 2020, despite serious cases of complement activation in boys treated with the experimental gene therapy in Phase Ib.

Pfizer will initiate a Phase III clinical trial testing its gene therapy PF-06939926 in the second half of 2020 with...

More from Gene Therapies

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

More from Advanced Therapies